BURLINGTON, ON – May 26, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian life sciences company specializing in innovative drug delivery solutions through its QuickStrip™ platform, today announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips—representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use.

While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy.

“These patent filings reflect a pivotal milestone in our commitment to reimagining nicotine consumption,” said Mark Upsdell, CEO of Rapid Dose Therapeutics. “By combining the convenience and familiarity of pouch formats with rapid action of our QuickStrip™ technology, we are delivering a discreet, fast-acting alternative for adult nicotine users looking to transition away from combustible tobacco and vaping.”

Unlike traditional pouches that rely on slower buccal absorption, RDT’s dissolvable QuickStrip™ nicotine strip enables nicotine delivery in under 2 minutes—offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences.

A Global Opportunity to Support Smoking and Vaping Cessation
According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that.

“Even a modest shift—just a small percentage of smokers transitioning to our QuickStrip nicotine products—could deliver a profound public health benefit,” said Jason Lewis, Co-Developer and Senior Vice President of RDT. “We believe this innovative format will resonate with a growing global population of adult users seeking modern, smoke-free solutions that are fast-acting, easy to use and unobtrusive.”

Building on Momentum: Partnership with Global Tobacco Leader
These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies – underscoring industry recognition and growing confidence in RDT’s ability to deliver innovative, consumer-centric nicotine alternatives.

“With the support of a global industry leader and the successful filing of these two key patents, we are strongly positioned to introduce our novel nicotine delivery solutions to regulated markets worldwide,” added Mark Upsdell, CEO of Rapid Dose Therapeutics.

RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters.

For further information and future updates, visit www.rapid-dose.com.

About Rapid Dose Therapeutics
Rapid Dose Therapeutics is a Canadian biotechnology company specializing in innovative, proprietary drug delivery technologies. Its flagship product, QuickStrip™, is a fast-dissolving oral thin film designed to deliver active ingredients rapidly, efficiently, and with high bioavailability.

About Aavishkar Oral Strips Pvt. Ltd.
Based in India, Aavishkar Oral Strips is a research-driven pharmaceutical and wellness company specializing in oral thin film technologies. The company partners globally to bring advanced delivery systems to the nutraceutical, pharmaceutical, and tobacco-free nicotine sectors.

Media Contact:
Investor Relations
Mark Upsdell
Rapid Dose Therapeutics Corp.
investorrelations@rapid-dose.com
+1 (416) 477-1052

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “intend”, “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, statements pertaining to the use of funds from the Financing and the anticipated closing of the Financing and Shares for Debt Transaction, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.  This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States. The securities described in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.